Intramuscular versus intravenous anti-D for preventing Rhesus alloimmunization during pregnancy
| dc.contributor.author | Okwundu, C.I. | |
| dc.contributor.author | Afolabi, B.B. | |
| dc.date.accessioned | 2020-11-09T12:04:55Z | |
| dc.date.available | 2020-11-09T12:04:55Z | |
| dc.date.issued | 2013 | |
| dc.description | Staff Publications | en_US |
| dc.description.abstract | Antibodies to the red cell Rhesus D (RhD) antigen can be produced during pregnancy in a RhD-negative mother carrying a RhDpositive fetus, in particular following feto-maternal haemorrhage at birth or following any procedure that may cause feto-maternal haemorrhage. While the first baby is usually not harmed, these antibodies may cause haemolytic disease of the fetus/newborn (HDFN) in subsequent RhD-positive babies. RhD incompatibility is a major cause of HDFN. To reduce the risk of HDFN, anti-D is given to RhD-negative mothers at 28 or 30 weeks of pregnancy and within 72 hours of potential maternal exposure to fetal red cells. Anit-D is currently available in both intramuscular (IM) and intravenous (IV) preparations. | en_US |
| dc.identifier.citation | Okwundu CI, Afolabi BB. Intramuscular versus intravenous anti-D for preventing Rhesus alloimmunization during pregnancy. Cochrane Database Syst Rev. 2013 Jan 31;(1):CD007885. doi: 10.1002/14651858.CD007885.pub2. Review. PubMed PMID: 23440818. | en_US |
| dc.identifier.uri | https://ir.unilag.edu.ng/handle/123456789/8908 | |
| dc.language.iso | en | en_US |
| dc.publisher | Cochrane Database Syst Rev | en_US |
| dc.subject | Antibodies | en_US |
| dc.subject | Pregnancy | en_US |
| dc.subject | Feto-maternal haemorrhage | en_US |
| dc.subject | Disease | en_US |
| dc.subject | Research Subject Categories::MEDICINE::Surgery::Obstetrics and women's diseases | en_US |
| dc.title | Intramuscular versus intravenous anti-D for preventing Rhesus alloimmunization during pregnancy | en_US |
| dc.type | Article | en_US |